A Study to Assess the Safety and Efficacy of a New Influenza Candidate Vaccine MVA-NP+M1 In Healthy Adults

Influenza Clinical Trial

Official title:

A Phase IIA Study to Assess the Safety and Efficacy of a New Influenza Candidate Vaccine MVA-NP+M1 In Healthy Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00993083
• Other study ID #: Flu002
• Status: Completed
• Phase: Phase 2
• First received: October 8, 2009
• Last updated: August 10, 2011
• Start date: June 2009
• Est. completion date: March 2010

Study information

• Verified date: January 2011
• Source: University of Oxford
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

This is a Phase IIa open label, non placebo controlled, non-randomised controlled challenge study. The primary objective of this study is to assess the safety of a new influenza vaccine, MVA-NP+M1, when administered as a single dose to healthy volunteers.

Initially two volunteers will be vaccinated and challenged with Influenza, followed by vaccination of a further 12 volunteers and an Influenza challenge of those 12 along with 12 non-vaccinated controls.

Description:

Antibodies against the external proteins of influenza can prevent the virus from infecting cells and either prevent infection or limit the spread of infection. However the surface proteins are highly variable and there is little antibody cross-reactivity between variants. Once a cell has been infected with the virus, it is then vulnerable to T cell attack resulting in the destruction of infected cells so that no more virus can be produced and the infection is controlled. There is evidence from clinical trials of influenza challenge, and animal models that T cell responses can protect in the absence of antibodies. Additionally, since T cells can recognise the highly conserved internal proteins of influenza, cross-subtype protection can be achieved.

Seasonal influenza infection results in a T cell response to the virus which can protect against subsequent infection. However over the course of a few years these responses decline below protective levels. The new vaccine being tested in this study is designed to boost these T cell responses back to protective levels. Even responses that may be too low to be reliably quantified by currently available assays may still be boosted to high levels by a single dose of recombinant MVA. Since the internal proteins vary little between influenza subtypes, this could result in a 'universal' vaccine against influenza A. If the need to continually reformulate the vaccine in response to mutations in the viral coat proteins can be removed, the universal vaccine could be produced in large amounts and used more widely than the existing seasonal 'flu vaccines, thus protecting the population against currently circulating viruses and new virus types that are at present only found in avian species.

There is very little polymorphism of NP and M1 between influenza A isolates. NP is 92% identical between H3N2 and H1N1 strains, and 91% identical between H3N2 and H5N1 strains. M1 is 95% identical between H3N2 and H1N1 strains, and 93% identical between H3N2 and H5N1 strains. This low level of variation appears to allow strong T cell cross-reactivity.

MVA is a highly attenuated strain of vaccinia virus that is unable to replicate efficiently in human cell lines and most mammalian cells. Viral replication is blocked at a late stage of virion assembly, so, importantly, viral and recombinant protein synthesis is unimpaired. This means that MVA is an efficient single round expression vector, incapable of causing infection in mammals. Replication-deficient recombinant MVA has been seen as an exceptionally safe viral vector. This safety in man is consistent with the avirulence of MVA in animal models, where recombinant MVAs have also been shown to be protectively immunogenic as vaccines against viral diseases and cancer. Importantly for a vaccine which may eventually be used in a large proportion of the population, recombinant MVAs expressing HIV antigens have been shown to be safe and immunogenic in HIV-infected subjects.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 27
• Est. completion date: March 2010
• Est. primary completion date: March 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Male or females aged 18 - 45 years

2. HI titre of less than 10

3. In general good health determined by a screening evaluation (medical history, physical examination, vital signs electrocardiogram (ECG) and clinical safety laboratory tests). ECG and spirometry will be performed at entry into quarantine rather than at screening visit

4. Females should fulfil the following criteria: (i) not pregnant or breastfeeding for the duration of the study and (ii) agree to use a reliable form of contraception for the duration of the study if sexually active

5. Negative HBsAg, HIV and HCV antibody screen

6. Negative class A drugs of abuse screen

7. Have not been vaccinated for Influenza virus in the current season or had a known influenza virus infection in the current season

8. Give written informed consent to participate

9. Willingness to remain in isolation during the challenge phase of the study and to comply with all study requirements

10. Willing and able to communicate with the Investigator and understand the requirements of the study

Exclusion Criteria:

1. Participation in another research study involving an investigational product in the 30 days preceding enrolment, or planned use of an IMP during the study period

2. Prior receipt of a recombinant MVA vaccine (vaccinees only)

3. Administration of immunoglobulins and/or any blood products within the three months preceding date of enrolment.

4. Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months

5. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. egg products. Any allergy to eggs or egg products

6. Any history of anaphylaxis in reaction to vaccination

7. Current cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)

8. Serious current psychiatric condition

9. Any other chronic illness requiring hospital specialist supervision

10. Suspected or known current injecting drug or alcohol abuse (as defined by an alcohol intake of greater than 42 units every week)

11. Any other significant disease, disorder or finding, which, in the opinion of the Investigators, may either put the volunteer at risk because of participation in the study, or may influence the result of the study, or the volunteer's ability to participate in the study.

12. Any clinically significant abnormal finding on screening biochemistry or haematology blood tests or urinalysis (see Table 1. Values outside the stated limits of Table 1 need written comment by a physician if considered clinically insignificant).

13. Venous access inadequate for phlebotomy demands of the study

14. Clinically significant abnormality on ECG

15. History since age 13 of asthma of any aetiology

16. Smokers who are unwilling or unable to desist for the duration of the inpatient challenge component of the study

17. Any anatomic or neurologic abnormality impairing the gag reflex or associated with a risk of aspiration

18. Presence of febrile illness or symptoms of upper respiratory tract infection on the day of vaccination (vaccination would be deferred)

19. Presence of febrile illness or symptoms suggestive of influenza between admission for influenza challenge and administration of the challenge inoculum

20. Use of inhaled, topical or systemic steroids in the six months preceding date of enrolment other than occasional use of cutaneous steroid if considered clinically irrelevant to the study by the Investigator..

21. Donation of blood or blood products within 7 days before study entry or at any time during the study

22. Donation of plasma within 7 days of study entry

23. Anti-'flu antibody titre of 10 or greater

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Intervention

Biological:
• MVA-NP+M1
Intramuscular injection at 1.5 x 10^8 pfu/ml at day 0

Locations

Country	Name	City	State
United Kingdom	Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital	Oxford	Oxfordshire
United Kingdom	Wellcome Trust Clinical Research Facility, University of Southampton	Southampton	Hampshire

Sponsors (2)

Lead Sponsor	Collaborator
University of Oxford	Wellcome Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety of a new Influenza vaccine, MVA-NP+M1, when administered to healthy volunteers		6 months	Yes
Secondary	Cellular immune response generated by a new influenza vaccine MVA- NP+M1 when administered as a single dose to healthy adults.		6 months	No